Dispensing Solution, Northwind Pharmaceuticals

Top 10 Dispensed Medications

Successful physician dispensing typically focuses on the most commonly prescribed medications for a particular practice. Nationally, the list below summarizes the most commonly non-controlled dispensed products:

  1. Simvastatin: Generic Zocor, a cholesterol-lowering statin drug — 94.1 million prescriptions
  1. Lisinopril: Generic Prinivil and Zestril, a blood pressure drug — 87.4 million prescriptions
  1. Levothyroxine: Generic Synthroid, synthetic thyroid hormone — 70.5 million prescriptions
  1. Amlodipine: Generic Norvasc, an angina/blood pressure drug — 57.2 million prescriptions
  1. Omeprazole: Generic Prilosec, an antacid drug — 53.4 million prescriptions (does not include over-the-counter sales)
  1. Azithromycin: Generic Z-Pak and Zithromax, an antibiotic used to treat bacterial infections (e.g. ear, skin) — 52.6 million prescriptions
  1. Amoxicillin: Amoxil, Trimox (various brand names), an antibiotic used to treat ear and bladder infections — 52.3 million prescriptions
  1. Metformin: Generic Glucophage, a diabetes drug — 48.3 million prescriptions
  1. HCTZ: Hydrochlorothiazide (various brand names), a water pill used to lower blood pressure — 47.8 million

Considering In-house Dispensing?       

Top 10 Dispensed MedicationsPharmaceutical dispensing programs at the clinic level typically provide treatments for acute symptoms using generic medications. A starting practice might start with 10 medications and only purchase 5-10 bottles of each. Some practices providing medication dispensing will offer 30-40 different products. Because these medications are prepackaged, there may be 3 or 4 different pill counts for the same drug. Find Out More   about how Northwind Pharmaceuticals could partner with you to consistently deliver the most needed medications to your patient populations.

Schedule a free claims analysis now.

Let’s Talk now

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading

Stewardship and the Beauty of Health Benefits

Phillip Berry | Oct 25th, 2024
The Beauty of Making a Difference Beauty in health benefits? What does that even mean? Think back on your experience as an HR/benefits professional. What are the peak moments? Most would agree that the high points are moments when they see their work directly impacting an employee or plan member. A time when the health … more »

continue reading